Thierry Laugel

Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France.

Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France.

Meiogenix SAS operates as a biotech company which develops breeding technologies. Its technology allows the modulation of the homologous recombination in eukaryotic cells. It facilitates the natural process that introduces genetic diversity in organisms allowing the generation of novel natural varieties. The company was founded by Giacomo Bastianelli and Alain Nicolas in 2011 and is headquartered in Paris, France.

PathoQuest SAS provides diagnostic development services for cancer and infectious diseases. Its services include viral safety testing, adventitious virus detection in cell lines under development and in Master Cell Banks, adventitious virus detection in viral stocks, and identify of the sequences of murine sarcoma virus. The company was founded by Luc Boblet and Marc Eloit on September 14, 2010 and is headquartered in Paris, France.

Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France.

Eurazeo Investment Managr - EIM SA (Eurazeo IM) is a Venture Capital firm founded in 1997 by Christophe Bavière and part of the Eurazeo Group. Eurazeo Investment Manager - EIM SA is headquartered in Paris with additional offices in Frankfurt, Shanghai and Seoul. The firm is formerly known as Idinvest Partners SA, former AGF Private Equity SA.

Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France.

PathoQuest SAS provides diagnostic development services for cancer and infectious diseases. Its services include viral safety testing, adventitious virus detection in cell lines under development and in Master Cell Banks, adventitious virus detection in viral stocks, and identify of the sequences of murine sarcoma virus. The company was founded by Luc Boblet and Marc Eloit on September 14, 2010 and is headquartered in Paris, France.

Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France.

Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France.

Eurazeo Investment Managr - EIM SA (Eurazeo IM) is a Venture Capital firm founded in 1997 by Christophe Bavière and part of the Eurazeo Group. Eurazeo Investment Manager - EIM SA is headquartered in Paris with additional offices in Frankfurt, Shanghai and Seoul. The firm is formerly known as Idinvest Partners SA, former AGF Private Equity SA.

Meiogenix SAS operates as a biotech company which develops breeding technologies. Its technology allows the modulation of the homologous recombination in eukaryotic cells. It facilitates the natural process that introduces genetic diversity in organisms allowing the generation of novel natural varieties. The company was founded by Giacomo Bastianelli and Alain Nicolas in 2011 and is headquartered in Paris, France.

BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands.

Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France.

PathoQuest SAS provides diagnostic development services for cancer and infectious diseases. Its services include viral safety testing, adventitious virus detection in cell lines under development and in Master Cell Banks, adventitious virus detection in viral stocks, and identify of the sequences of murine sarcoma virus. The company was founded by Luc Boblet and Marc Eloit on September 14, 2010 and is headquartered in Paris, France.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.

Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France.

Argobio SAS is a start-up studio founded in 2021 and based in Paris, FR. The company was initiated by Kurma Partners, a leading healthcare venture capital firm based in France, and Bpifrance, the French national investment bank. The French company aims to nurture and launch at least five breakthrough biotech companies over the next five years by sourcing innovative early-stage projects from renowned European academic research institutions. The focus is on selected therapeutic areas, including rare diseases, neurological disorders, oncology, and immunology. Argobio will identify, select, and incubate these projects up to company creation and beyond, providing broad expertise in the discovery and development of novel drugs with a team of highly experienced biotech entrepreneurs. The internal team is led by Yves Ribeill, Neill Mackenzie, Poul Sørensen, and Rémi Soula. Thierry Laugel, Managing Partner at Partners, is the President of Argobio. Kurma and Bpifrance were joined by complementary strategic investors, Angelini Pharma, a private international pharmaceutical company, Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, an internationally renowned center for biomedical research.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.

Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France.

Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France.

Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France.

PathoQuest SAS provides diagnostic development services for cancer and infectious diseases. Its services include viral safety testing, adventitious virus detection in cell lines under development and in Master Cell Banks, adventitious virus detection in viral stocks, and identify of the sequences of murine sarcoma virus. The company was founded by Luc Boblet and Marc Eloit on September 14, 2010 and is headquartered in Paris, France.

Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France.

Eurazeo Investment Managr - EIM SA (Eurazeo IM) is a Venture Capital firm founded in 1997 by Christophe Bavière and part of the Eurazeo Group. Eurazeo Investment Manager - EIM SA is headquartered in Paris with additional offices in Frankfurt, Shanghai and Seoul. The firm is formerly known as Idinvest Partners SA, former AGF Private Equity SA.

Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France.

Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France.

Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France.

Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France.

Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France.

Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France.

Meiogenix SAS operates as a biotech company which develops breeding technologies. Its technology allows the modulation of the homologous recombination in eukaryotic cells. It facilitates the natural process that introduces genetic diversity in organisms allowing the generation of novel natural varieties. The company was founded by Giacomo Bastianelli and Alain Nicolas in 2011 and is headquartered in Paris, France.

Meiogenix SAS operates as a biotech company which develops breeding technologies. Its technology allows the modulation of the homologous recombination in eukaryotic cells. It facilitates the natural process that introduces genetic diversity in organisms allowing the generation of novel natural varieties. The company was founded by Giacomo Bastianelli and Alain Nicolas in 2011 and is headquartered in Paris, France.

Meiogenix SAS operates as a biotech company which develops breeding technologies. Its technology allows the modulation of the homologous recombination in eukaryotic cells. It facilitates the natural process that introduces genetic diversity in organisms allowing the generation of novel natural varieties. The company was founded by Giacomo Bastianelli and Alain Nicolas in 2011 and is headquartered in Paris, France.

Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France.

Kurma Biofund seeks investment opportunities in life science and biotechnology companies located in Europe. The investments are done in cooperation with medical institutes and universities such as Institut Pasteur and Institut Curie. Its investment size ranges between €0.10 and €6 million.

Eurazeo Investment Managr - EIM SA (Eurazeo IM) is a Venture Capital firm founded in 1997 by Christophe Bavière and part of the Eurazeo Group. Eurazeo Investment Manager - EIM SA is headquartered in Paris with additional offices in Frankfurt, Shanghai and Seoul. The firm is formerly known as Idinvest Partners SA, former AGF Private Equity SA.

Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France.

Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France.

Eurazeo Investment Managr - EIM SA (Eurazeo IM) is a Venture Capital firm founded in 1997 by Christophe Bavière and part of the Eurazeo Group. Eurazeo Investment Manager - EIM SA is headquartered in Paris with additional offices in Frankfurt, Shanghai and Seoul. The firm is formerly known as Idinvest Partners SA, former AGF Private Equity SA.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.

PathoQuest SAS provides diagnostic development services for cancer and infectious diseases. Its services include viral safety testing, adventitious virus detection in cell lines under development and in Master Cell Banks, adventitious virus detection in viral stocks, and identify of the sequences of murine sarcoma virus. The company was founded by Luc Boblet and Marc Eloit on September 14, 2010 and is headquartered in Paris, France.

Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.

BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands.

Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France.

Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France.

Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France.

Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France.

Eurazeo Investment Managr - EIM SA (Eurazeo IM) is a Venture Capital firm founded in 1997 by Christophe Bavière and part of the Eurazeo Group. Eurazeo Investment Manager - EIM SA is headquartered in Paris with additional offices in Frankfurt, Shanghai and Seoul. The firm is formerly known as Idinvest Partners SA, former AGF Private Equity SA.

Eurazeo Investment Managr - EIM SA (Eurazeo IM) is a Venture Capital firm founded in 1997 by Christophe Bavière and part of the Eurazeo Group. Eurazeo Investment Manager - EIM SA is headquartered in Paris with additional offices in Frankfurt, Shanghai and Seoul. The firm is formerly known as Idinvest Partners SA, former AGF Private Equity SA.

Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.

Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France.

Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France.

Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France.

Eurazeo Investment Managr - EIM SA (Eurazeo IM) is a Venture Capital firm founded in 1997 by Christophe Bavière and part of the Eurazeo Group. Eurazeo Investment Manager - EIM SA is headquartered in Paris with additional offices in Frankfurt, Shanghai and Seoul. The firm is formerly known as Idinvest Partners SA, former AGF Private Equity SA.